Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 2,236 shares at $250.04 ($557K) on 2022-02-02, disclosed to the SEC on 2022-02-03.
Open-market sale of $557k VRTX by EVP, Cell & Genetic Therapies. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $243.64 | 526 | $128K | 23.0% |
| 2 | $250.04 | 670 | $168K | 30.1% |
| 3 | $250.04 | 670 | $168K | 30.1% |
| 4 | $251.47 | 141 | $35K | 6.4% |
| 5 | $253.07 | 149 | $38K | 6.8% |
| 6 | $253.95 | 64 |
| $16K |
| 2.9% |
| 7 | $254.54 | 16 | $4K | 0.7% |
| Total | $248.97 avg | 2,236 | $557K | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |